LSA4 Protocol for the Treatment of Advanced Pediatric and Adolescent Non-Hodgkins Lymphoma

Non-Hodgin's lymphoma is curable in 76% of patients. In nonlymphoblastic lymphmas, cancer may return on average 3 months from beginning treatment and for lymphoblastic lymphomas, 6 months. To aggressively treat this cancer this study uses effective drugs in three parts:

* Induction ends on day 19 * Consolidation ends on day 38 or 42 * Maintenance may include up to 6 cycles

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Non-Hodgkin's Lymphoma Hemic and Lymphatic Diseases Immune System Diseases Immunoproliferative Disorders Lymphatic Diseases Lymphoma Lymphoma, Non-Hodgkin Lymphoproliferative Disorders Neoplasms Neoplasms by Histologic Type

Age range

Up to 21 year

Sex eligibility

All sexes

Study type

Interventional

Phase

Phase 2

Primary location

Memorial Sloan-Kettering Cancer Center

New York, 10065, United States

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

Non-Hodgkin's Lymphoma stages III, IV, IVA with

T cell lymphomas, any primary site irrespective of LDH level
large cell lymphomas, any primary site irrespective of LDH level
B cell lymphomas, any primary site with initial LDH of less than 500

Exclusion criteria

B cell lymphomas, any primary site with initial LDH of less than 500 and initial CNS or bone involvement

Treatment and study plan

LSA4, Cyclophosphamide, Methotrexate, Daunomycin, L-asparaginase, BCNU

Drug

LSA4 intervention includes three phases: induction, consolidation and maintenance

Primary outcomes

Complete Remission

Time frame: 330 Days

The number of patients who achieved a complete remission as a result of treatment

Sponsors and collaborators

Lead sponsor

Memorial Sloan Kettering Cancer Center

Other

Registry information

Important dates

Study start: 1990
Primary completion: 2008
Study completion: 2008
First posted: Feb 8, 2008
Registry last updated: Sep 28, 2023

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.

Completed